Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery
Randomized Clinical Trial for Comparison Between the Anxiolytic Effect of Virtual Reality Immersion Versus Midazolam Premedication in Patients Undergoing Dacryocystorhinostomy Surgery
Cairo University
40 participants
Jun 1, 2025
INTERVENTIONAL
Conditions
Summary
The aim is to investigate the anxiolytic effect, and hemodynamic stability of using virtual reality immersion in adult patients undergoing Dacryocystorhinostomy (DCR) operation under general anesthesia and to compare its effect to that of using Midazolam as a premedication.
Eligibility
Inclusion Criteria4
- Aged 18-65.
- Both sexes.
- American Society of Anesthesiologists (ASA) classification: I - II.
- Patient undergoing Dacryocystorhinostomy Surgery (DCR) operation under general anesthesia.
Exclusion Criteria10
- Patient refusal.
- Patients with cardiac diseases.
- Patients with renal diseases.
- Patients with drug sensitivity and seizures.
- Substance abuse and addiction.
- Claustrophobia.
- Patients with cerebrovascular disease.
- Psychiatric and cognitive disorder.
- Patients with severe teary eyes and blurring of vision.
- Patients who express discomfort during the test.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patient will undergo virtual reality (VR) immersion using oculus.
Patient will receive midazolam premedication only.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07050095